A study of 3,000 women found that those expose to more ultraviolet radiation had a decreased risk of ovarian cancer and an increased risk of borderline tumors.
See the full abstract here
This article was updated in February 2026 to reflect NCCN’s release of the 2026 Guidelines for Cervical Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer, and the 2025 Patient Guidelines for Ovarian, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
$1 million global research award, plus an additional $1 million in compute support, advances AI-driven efforts to personalize ovarian cancer care The Global Ovarian Cancer Research Consortium today awarded its inaugural AI Accelerator Grant to an international team of researchers to examine whether artificial intelligence (AI) can improve how survival and treatment response are predicted … Continued
The U.S. Food and Drug Administration (FDA) has approved the first immunotherapy regimen shown to extend survival in a subset of ovarian cancer patients. The FDA authorized Keytruda (pembrolizumab), made by Merck, in combination with chemotherapy, for PD-L1–positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancers. Keytruda plus weekly Taxol (paclitaxel), with or without … Continued
Get email updates about research news, action alerts, and ways to join the fight.